CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8+T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, a classically described mechanism of tumor immune escape is tumor MHC-I downregulation. Here, we report that CD8+T cells maintain the capacity to kill tumor cells that are entirely devoid of MHC-I expression. This capacity proves to be dependent instead on interactions between T cell natural killer group 2D (NKG2D) and tumor NKG2D ligands (NKG2DLs), the latter of which are highly expressed on MHC-loss variants. Necessarily, tumor cell killing in these instances is antigen independent, although prior T cell antigen-specific activation is required and can be furnished by myeloid cells or even neighboring MHC-replete tumor cells. In this manner, adaptive priming can beget innate killing. These mechanisms are active in vivo in mice as well as in vitro in human tumor systems and are obviated by NKG2D knockout or blockade. These studies challenge the long-advanced notion that downregulation of MHC-I is a viable means of tumor immune escape and instead identify the NKG2D–NKG2DL axis as a therapeutic target for enhancing T cell-dependent anti-tumor immunity against MHC-loss variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
de Vries, N. L., van de Haar, J., Veninga, V., Chalabi, M., Ijsselsteijn, M. E., van der Ploeg, M., van den Bulk, J., Ruano, D., van den Berg, J. G., Haanen, J. B., et al. (2023) · Nature · doi:10.1038/s41586-022-05593-1 · Cited by 311
TCR-signaling events in cellular metabolism and specialization
Chisolm, D. A., & Weinmann, A. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00292 · Cited by 26
Cited by
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“This is accomplished through interactions between T cell NKG2D and tumor NKG2D ligands [30].”
BackgroundDesign and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
Song, K., & Pun, S. H. (2024) · BME Frontiers · doi:10.34133/bmef.0038 · Cited by 20
Xue, Y., Wang, Q., Chen, Y., Zhang, X., Tang, J., Liu, Y., & Liu, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403998 · Cited by 14
Metadata
- Authors
- Lerner, E. C., Woroniecka, K. I., D’Anniballe, V. M., Wilkinson, D. S., Mohan, A. A., Lorrey, S. J., Waibl-Polania, J., Wachsmuth, L. P., Miggelbrink, A. M., Jackson, J. D., Cui, X., Raj, J. A., Tomaszewski, W. H., Cook, S. L., Sampson, J. H., Patel, A. P., Khasraw, M., Gunn, M. D., & Fecci, P. E.
- Venue
- Nature Cancer
- Published
- 2023-08-03
- Volume
- 4
- Issue
- 9
- Pages
- 1258-1272
- ISSN
- 2662-1347 (ISSN-L)
- OpenAlex
- W4385543644
- Cited by
- 136
- References
- 6
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis. https://app.cochat.ai/papers/10.1038/s43018-023-00600-4
- The paper
- Lerner, E. C., Woroniecka, K. I., D’Anniballe, V. M., Wilkinson, D. S., Mohan, A. A., Lorrey, S. J., Waibl-Polania, J., Wachsmuth, L. P., Miggelbrink, A. M., Jackson, J. D., Cui, X., Raj, J. A., Tomaszewski, W. H., Cook, S. L., Sampson, J. H., Patel, A. P., Khasraw, M., Gunn, M. D., & Fecci, P. E. (2023). CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis. Nature Cancer. https://doi.org/10.1038/s43018-023-00600-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.